Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

ABSTRACT:

SUBMITTER: Lode L 

PROVIDER: S-EPMC5865441 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature